|
Adimmune Corporation is a vaccine and biologics manufacturer founded in 1965. The company produces trivalent and quadrivalent influenza vaccines, Japanese Encephalitis Vaccine, Tetanus Toxoid, and purified Tuberculin. It operates as a contract development and manufacturing organization (CDMO), providing collaborative development, technical cooperation, filling and packaging services, and regulatory support. Adimmune supports Sanofi Pasteur in the commercialization of recombinant protein quadrivalent influenza vaccines in the United States and cooperates with Shenzhen Techdow to produce low-molecular enoxaparin sodium. The company has engaged in technical cooperation with Kitasato Daiichi Sankyo and Crucell, and signed a memorandum of understanding with Becton Dickinson. Its products are supplied to markets in Taiwan, China, and Southeast Asia, and it participates in the WHO Pandemic Influenza Preparedness Framework. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Drug Manufacturers - General | Homepage adimmune.com.tw |
| Sector Healthcare | IR page adimmune.com.tw/en/investor | |
|
Tags
vaccines, biologics, contract manufacturing, influenza vaccines, tetanus vaccines, cell culture, aseptic filling, regulatory support, AdimFlu-S, Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine, Tetanus Toxoid, purified Tuberculin, Kitasato Daiichi Sankyo, Crucell, Becton Dickinson, Sanofi Pasteur, Shenzhen Techdow
|
Press page adimmune.com.tw/en/news |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 6.679B |
| Market cap (USD) | $ 202.712M |
| P/E | 93.24 |
| PEG | — |
| P/BV | 1.38 |
| P/S | 4.15 |
| P/OCF | 9.99 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -4.7% |
| ROI | -4.9% |
| ROIC | -5.5% |
| Profit margin | -17.1% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -56.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.402B | 1.557B | 1.785B | 2.252B | 1.641B | 1.869B | 1.3B | 822.366M | 562.743M | 606.725M | 290.737M | 480.506M | 414.093M |
| Net profit | -239.889M | -242.75M | -639.891M | 290.975M | 43.066M | 1.241B | -280.678M | -609.117M | -760.176M | -595.352M | -761.087M | -614.422M | -600.453M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 18.95 | 20.1 | 33.15 | 35.6 | 44.65 | 56.1 | — | — | — | — | — | — | — |
| Price performance 12m | -0.06 | -0.39 | -0.07 | -0.2 | -0.2 | — | — | — | — | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Adimmune Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
